Chris Kim, Liminatus Pharma CEO

December 2, 2022 09:40 AM ESTUpdated 10:27 AM

A fledgling biotech goes SPAC route to bankroll cancer vaccine, CAR-T and CD47

Kyle LaHucik

Senior Reporter

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

view job offer post your job now

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

Revolution’s KRAS drugs appear competitive in several lung cancer settings

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges